logo
Plus   Neg
Share
Email

Roche Reports Positive Data From OCREVUS Phase III Open-label Extension Studies

Roche (RHHBY.PK) said data from three phase III open-label extension studies demonstrated that patients who were treated with OCREVUS for six years or more had reduced risk of disability progression in relapsing multiple sclerosis and primary progressive multiple sclerosis. The company said the results show earlier treatment with OCREVUS reduced the risk of disability progression and the effect was sustained over time.

OCREVUS is the first and only therapy approved for both relapsing multiple sclerosis and primary progressive multiple sclerosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Transportation says it received lesser number of complaints from consumers about airline services in August. In August, DOT received 1,712 complaints about airline service from consumers, down 1.0% from the total of 1,730 filed in August 2018 and down 8.7% from the 1,875 received... Shares of Netflix Inc. (NFLX) jumped 7% in extended trading session Wednesday after the online-video streaming giant said it added more subscribers in the third quarter after a disappointing previous quarter. The company's third-quarter earnings topped Wall Street estimates, as revenues surged 31%. Netflix... Alcoa Corp. (AA), the largest producer of aluminum in the US, Wednesday posted a wider-than-expected loss for the third quarter, reflecting a drop in revenues as well as one-time charges related to two smelters in Spain. The company also announced a "portfolio review" of its smelting and refining capacity...
Follow RTT
>